Oculis Holding AG (OCS)
Free
No email, no account, no signup.
Pulling latest news for Oculis Holding AG…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Ophthalmology biotechnology
Market Cap
$648M
We're already tracking Oculis Holding AG — here are the latest events we've registered
Recent News
- On May 29, 2026, Oculis announced that its Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed to meet primary endpoints, resulting in the cancellation of its planned FDA filing. In June 2026, the company shifted focus to its remaining pipeline, randomizing the first patient in the PREDICT-1 trial for dry eye disease. Several law firms have since launched investigations into the company regarding potential securities law violations following the trial failure.
Want to know how this news affects Oculis Holding AG? Order the analysis.
Order analysis – What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Oculis Holding AG will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.